1. Feasibility and country strategy
Realistic enrollment modeling by country and site, with activation timelines that account for local submission sequencing and permit lead times.
Solutions · Clinical Operations | Global Clinical Trial Management | Guosa Life Sciences
Integrated Clinical Operations That Keep Studies Moving Forward
Successful clinical trials are built on disciplined execution, proactive oversight and seamless coordination. As protocols become more complex and studies span multiple countries, sponsors require operations partners capable of managing scientific, operational, regulatory and logistical activities within one integrated model.
Overview
Guosa Life Sciences provides comprehensive Clinical Operations services supporting Phase I–IV studies through coordinated project management, site management, monitoring and performance management.
Our multidisciplinary teams combine scientific expertise with quality-driven execution, delivering studies efficiently while maintaining the highest standards of participant safety, compliance and data integrity.

Capabilities
Lifecycle
The GLS Advantage
Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.
The capability
We run Phase I–IV studies end to end: feasibility and country selection, site identification and qualification, activation, monitoring, data flow oversight, and close-out. Study teams are built around a named project lead who stays with the program, so the people who scoped the work are the people accountable for delivering it.
Activation is where most timelines are lost, and it is where we concentrate. Site qualification runs in parallel with regulatory submission rather than after it, essential documents are collected against a tracked checklist from first contact, and contract and budget negotiation begins before approval rather than on receipt of it. The sequence is deliberate: every week saved before green light is a week that does not need to be recovered during recruitment.
Regulatory considerations
ICH E6(R3) has changed what sponsors and inspectors expect of clinical operations. The principles and Annex 1 came into effect on 23 July 2025, Health Canada implemented on 1 April 2026, and Annex 2, covering decentralized and pragmatic designs and real-world data sources, takes effect on 15 January 2027. The practical consequence is that protocols are now expected to identify critical-to-quality factors explicitly, with the associated risks and mitigations documented rather than implied.
That shifts monitoring from a volume exercise to a targeted one. Centralized review of accumulating data determines where on-site effort is directed, and the rationale for that direction has to be evidenced. We build the critical-to-quality framework into the monitoring plan at start-up, so the risk assessment an inspector asks for exists from day one rather than being reconstructed at close-out.
How an engagement runs
Realistic enrollment modeling by country and site, with activation timelines that account for local submission sequencing and permit lead times.
Parallel regulatory, ethics, contract and site qualification workstreams against one tracked activation plan.
Risk-based monitoring driven by centralized data review, with defined escalation and a single point of accountability to the sponsor.
Site closure, essential document reconciliation, TMF completeness review and archive-ready handover.
What you receive
An activation plan with modeled timelines by country. A critical-to-quality framework and risk-based monitoring plan. Centralized performance reporting against enrollment and quality metrics. An inspection-ready trial master file at close-out.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
FAQ
Phase I through Phase IV, including post-marketing and observational studies, across diverse therapeutic areas.
Yes, on-site, remote and risk-based monitoring models tailored to each study's risk profile and complexity.
Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.